Menu

 

Analysis

Multiple sclerosis risk sharing scheme: a costly failure

BMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c1672 (Published 4 June 2010)
Cite this as: BMJ 2010;340:c1672

Related articles

Feature: NICE is dead; long live NICE

Published 24 April 2013; BMJ 346 doi: 10.1136/bmj.f2546

Letter: Response from chair of scientific advisory committee

Published 7 July 2010; BMJ 341 doi: 10.1136/bmj.c3590

Letter: Outcome based schemes are more common than you think

Published 7 July 2010; BMJ 341 doi: 10.1136/bmj.c3588

Analysis: Continuing the multiple sclerosis risk sharing scheme is unjustified

Published 4 June 2010; BMJ 340 doi: 10.1136/bmj.c1786

Analysis: Commentary: Scheme has benefited patients

Published 4 June 2010; BMJ 340 doi: 10.1136/bmj.c2707

Editorial: The multiple sclerosis risk sharing scheme

Published 3 June 2010; BMJ 340 doi: 10.1136/bmj.c2882

Analysis: Commentary: Outcome measures were flawed

Published 3 June 2010; BMJ 340 doi: 10.1136/bmj.c2693

Education and debate: Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

Published 15 February 2003; BMJ 326 doi: 10.1136/bmj.326.7385.388

Data supplement

HTML Page - index.htslp

Published

HTML Page - index.htslp

Published

See more

Research: Risk of incident diabetes among patients treated with statins: population based study

Published 23 May 2013; BMJ 346 doi: 10.1136/bmj.f2610

Editorial: Statins and the risk of developing diabetes

Published 23 May 2013; BMJ 346 doi: 10.1136/bmj.f3156

Feature: The long road to ensuring patient safety in NHS hospitals

Published 23 May 2013; BMJ 346 doi: 10.1136/bmj.f3029

Practice: Pelvic inflammatory disease

Published 23 May 2013; BMJ 346 doi: 10.1136/bmj.f3189

This article has been cited by other articles:

Latest comments and most commented

THIS WEEK'S POLL

Read related article

See previous polls